Medical Treatment for Rheumatic Diseases
Identifieur interne : 003071 ( Main/Exploration ); précédent : 003070; suivant : 003072Medical Treatment for Rheumatic Diseases
Auteurs : H. A. Bird [Royaume-Uni]Source :
- The Journal of the Royal Society for the Promotion of Health [ 1466-4240 ] ; 1990-10.
English descriptors
- Teeft :
- Arthritis, Catabolic disease, Chemical structure, Clinical trials, Daily dosing, Diseased joints, Drug therapy, Early stage, Erosion formation, Full blood, Hospital prescription, Injectable gold, Lower dose, Marrow aplasia, Normochromic normocytic anaemia, Nsaid, Occupational therapist, Regional office, Rheumatoid, Rheumatoid arthritis, Rheumatoid disease, Rheumatoid factor, Self medication, Specific indication, Thiol group.
Abstract
REST, PHYSIOTHERAPY, joint protection, patient education and counselling all play an important role alongside drug therapy and sur gery in the management of a chronic disorder such as theumatoid arthritis. Patients expect their physician to take the initiative in integrating the members of the multi-disciplinary team devoted to their care. The physician will also instigate drug therapy. In early disease, an analgesic ('for pain') may supplement a non-steroidal anti-inflammatory drug ('for stiffness'). A variety of such drugs are available with various advantages and disadvantages. For more severe, progressive disease a 'second-line' or disease-modifying drug may be prescribed. Typical examples are injectable gold, penicillamine, anti malarials, sulphasalazine and methotrexate. The pres cription of any of these represents a calculated risk: the benefits of treatment have to be balanced against the likely side-effects. A variety of intra-articular treatments are also available for providing some localisation of response and sometimes obviating the need for surgery which should be the subject of close collaboration between the rheumatologists and orthopaedic surgeons.
Url:
DOI: 10.1177/146642409011000503
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002594
- to stream Istex, to step Curation: 002594
- to stream Istex, to step Checkpoint: 001E42
- to stream Main, to step Merge: 003140
- to stream Main, to step Curation: 003071
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Medical Treatment for Rheumatic Diseases</title><author wicri:is="90%"><name sortKey="Bird, H A" sort="Bird, H A" uniqKey="Bird H" first="H. A." last="Bird">H. A. Bird</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B42BB046CB5B7AFD9BB442E75DA806227C1F5DFC</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1177/146642409011000503</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-XWXJ2N24-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002594</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002594</idno><idno type="wicri:Area/Istex/Curation">002594</idno><idno type="wicri:Area/Istex/Checkpoint">001E42</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E42</idno><idno type="wicri:doubleKey">1466-4240:1990:Bird H:medical:treatment:for</idno><idno type="wicri:Area/Main/Merge">003140</idno><idno type="wicri:Area/Main/Curation">003071</idno><idno type="wicri:Area/Main/Exploration">003071</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Medical Treatment for Rheumatic Diseases</title><author wicri:is="90%"><name sortKey="Bird, H A" sort="Bird, H A" uniqKey="Bird H" first="H. A." last="Bird">H. A. Bird</name><affiliation wicri:level="4"><orgName type="university">Université de Leeds</orgName><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of the Royal Society for the Promotion of Health</title><idno type="ISSN">1466-4240</idno><idno type="eISSN">1757-9147</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="1990-10">1990-10</date><biblScope unit="volume">110</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="160">160</biblScope></imprint><idno type="ISSN">1466-4240</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1466-4240</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Arthritis</term><term>Catabolic disease</term><term>Chemical structure</term><term>Clinical trials</term><term>Daily dosing</term><term>Diseased joints</term><term>Drug therapy</term><term>Early stage</term><term>Erosion formation</term><term>Full blood</term><term>Hospital prescription</term><term>Injectable gold</term><term>Lower dose</term><term>Marrow aplasia</term><term>Normochromic normocytic anaemia</term><term>Nsaid</term><term>Occupational therapist</term><term>Regional office</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid disease</term><term>Rheumatoid factor</term><term>Self medication</term><term>Specific indication</term><term>Thiol group</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">REST, PHYSIOTHERAPY, joint protection, patient education and counselling all play an important role alongside drug therapy and sur gery in the management of a chronic disorder such as theumatoid arthritis. Patients expect their physician to take the initiative in integrating the members of the multi-disciplinary team devoted to their care. The physician will also instigate drug therapy. In early disease, an analgesic ('for pain') may supplement a non-steroidal anti-inflammatory drug ('for stiffness'). A variety of such drugs are available with various advantages and disadvantages. For more severe, progressive disease a 'second-line' or disease-modifying drug may be prescribed. Typical examples are injectable gold, penicillamine, anti malarials, sulphasalazine and methotrexate. The pres cription of any of these represents a calculated risk: the benefits of treatment have to be balanced against the likely side-effects. A variety of intra-articular treatments are also available for providing some localisation of response and sometimes obviating the need for surgery which should be the subject of close collaboration between the rheumatologists and orthopaedic surgeons.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Yorkshire-et-Humber</li></region><settlement><li>Leeds</li></settlement><orgName><li>Université de Leeds</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Bird, H A" sort="Bird, H A" uniqKey="Bird H" first="H. A." last="Bird">H. A. Bird</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B42BB046CB5B7AFD9BB442E75DA806227C1F5DFC
|texte= Medical Treatment for Rheumatic Diseases
}}
| This area was generated with Dilib version V0.6.33. |  |